Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System

STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01877902

Enrollment

190

Registered

2013-06-14

Start date

2011-10-31

Completion date

Unknown

Last updated

2014-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Brief summary

STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients over 18 years * Confirmed diagnosis of metastatic NSCLC * Pemetrexed Starts 1st line (either induction or maintenance) in any of the following periods: * January 1, 2010 to March 31, 2010 * October 1, 2011 to December 31, 2011

Exclusion criteria

* Patients receiving pemetrexed within a clinical trial protocol because it is an experimental environment that does not reflect clinical practice.

Design outcomes

Primary

Measure	Time frame
Determine utilization profile (line treatment and scheme used) of pemetrexed in patients with non-small cell lung cancer metastatic (CPNMm) in Andalusia.	12 months

Secondary

Measure	Time frame
1) Determine the progression-free survival and overall survival 2) Evaluate the degree of adherence in prescribing pemetrexed patients with CPNMm in Andalusia approved indications, the recommendations of the Pharmacy and Therapeutics Committees and	12 months

Countries

Spain

Contacts

Primary ContactJavier Bautista Paloma

955 01 20 00

Backup ContactMaría del Mar Benjumea Vargas

gestiondeensayosclinicos.fps@juntadeandalucia.es

Outcome results